In yesterday’s Wall Street session, Pacific Biosciences of California Inc (NASDAQ:PACB) shares traded at $1.65, up 3.12% from the previous session.
PACB stock price is now -54.43% away from the 50-day moving average and -78.56% away from the 200-day moving average. The market capitalization of the company currently stands at $449.26M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On April 18, 2024, Goldman Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $7 to quote $2.50, while ‘Stephens’ rates the stock as ‘Overweight’
In other news, Meline David W, Director bought 40,000 shares of the company’s stock on Mar 06 ’24. The stock was bought for $176,160 at an average price of $4.40. Upon completion of the transaction, the Director now directly owns 40,000 shares in the company, valued at $66000.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’24, HENRY CHRISTIAN O sold 14,177 shares of the business’s stock. A total of $69,056 was realized by selling the stock at an average price of $4.87. This leaves the insider owning 2,596,670 shares of the company worth $4.28 million. A total of 6.08% of the company’s stock is owned by insiders.
During the past 12 months, Pacific Biosciences of California Inc has had a low of $1.25 and a high of $14.55. As of last week, the company has a debt-to-equity ratio of 1.33, a current ratio of 7.81, and a quick ratio of 7.21.
According to the Medical Devices Company, earnings per share came in at -0.36, missing analysts’ expectations of -0.33 by -0.03. This compares to -$0.37 EPS in the same period last year. The net profit margin was -153.05% and return on equity was -48.53% for PACB. The company reported revenue of $58.36 million for the quarter, compared to $27.35 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 113.35 percent. For the current quarter, analysts expect PACB to generate $42.96M in revenue.
